Drug Trial Radar · NCT04551911
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Last checked: Nov 19, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
171
Actual
Start
Nov 2, 2020
Primary completion
Oct 8, 2021
Study completion Oct 8, 2021
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
Conditions
- COVID-19
- Coronavirus
- SARS-CoV2 Infection
Interventions
RayaldeeDrug
30 mcg calcifediol Extended-Release (ER) Capsule
PlaceboDrug
0 mcg calcifediol Extended-Release (ER) Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).Time frame: 14 days
- Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.Time frame: 42 days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
OPKO Investigative Site
San Francisco, California
OPKO Investigative Site
Miami, Florida
OPKO Investigative Site
Miami, Florida
OPKO Investigative Site
Evanston, Illinois
OPKO Investigative Site
Laurel, Maryland
OPKO Investigative Site
Farmington Hills, Michigan
OPKO Investigative Site
Jackson, Michigan
OPKO Investigative Site
Sterling Heights, Michigan
OPKO Investigative Site
Brookhaven, Mississippi
OPKO Investigative Site
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.